On June 24, 2025, MAIA Biotechnology, Inc. entered into a stock purchase agreement to sell $587,905 worth of shares to Prevail Partners, LLC, with an upfront payment of $58,800 and subsequent payments totaling $14,697.333 each for 36 months. The transaction will fund a Phase 3 study on lung cancer treatments.